Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.

Tóth Z, Forgács L, Locke JB, Kardos G, Nagy F, Kovács R, Szekely A, Borman AM, Majoros L.

J Antimicrob Chemother. 2019 Sep 20. pii: dkz390. doi: 10.1093/jac/dkz390. [Epub ahead of print]

PMID:
31539426
2.

Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.

Wiederhold NP, Locke JB, Daruwala P, Bartizal K.

J Antimicrob Chemother. 2018 Nov 1;73(11):3063-3067. doi: 10.1093/jac/dky280.

PMID:
30032217
3.

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Locke JB, Almaguer AL, Donatelli JL, Bartizal KF.

Infect Dis Obstet Gynecol. 2018 Feb 22;2018:7040498. doi: 10.1155/2018/7040498. eCollection 2018.

4.

In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis.

Boikov DA, Locke JB, James KD, Bartizal K, Sobel JD.

J Antimicrob Chemother. 2017 May 1;72(5):1355-1358. doi: 10.1093/jac/dkx008.

5.

Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species.

Locke JB, Almaguer AL, Zuill DE, Bartizal K.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6100-7. doi: 10.1128/AAC.00620-16. Print 2016 Oct.

6.

CD101: a novel long-acting echinocandin.

Zhao Y, Perez WB, Jiménez-Ortigosa C, Hough G, Locke JB, Ong V, Bartizal K, Perlin DS.

Cell Microbiol. 2016 Sep;18(9):1308-16. doi: 10.1111/cmi.12640. Epub 2016 Jul 22.

7.

Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.

Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF.

Diagn Microbiol Infect Dis. 2015 Feb;81(2):112-8. doi: 10.1016/j.diagmicrobio.2014.08.011. Epub 2014 Aug 30.

PMID:
25488274
8.

Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene.

Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Denys GA, Goering RV, Shaw KJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6592-8. doi: 10.1128/AAC.03493-14. Epub 2014 Aug 25.

9.

Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.

Locke JB, Zuill DE, Scharn CR, Deane J, Sahm DF, Goering RV, Jenkins SG, Shaw KJ.

Antimicrob Agents Chemother. 2014 Nov;58(11):6949-52. doi: 10.1128/AAC.03380-14. Epub 2014 Aug 18.

10.

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.

Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P.

Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29.

PMID:
24875463
11.

Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, Lam T, Zhang J, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J.

PLoS One. 2013 Dec 26;8(12):e84409. doi: 10.1371/journal.pone.0084409. eCollection 2013.

12.

Tedizolid for the management of human infections: in vitro characteristics.

Locke JB, Zurenko GE, Shaw KJ, Bartizal K.

Clin Infect Dis. 2014 Jan;58 Suppl 1:S35-42. doi: 10.1093/cid/cit616. Review.

PMID:
24343830
13.

Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete.

Jang KH, Nam SJ, Locke JB, Kauffman CA, Beatty DS, Paul LA, Fenical W.

Angew Chem Int Ed Engl. 2013 Jul 22;52(30):7822-4. doi: 10.1002/anie.201302749. Epub 2013 Jun 17. Erratum in: Angew Chem Int Ed Engl. 2014 Jan 13;53(3):621.

14.

Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design.

Teng M, Hilgers MT, Cunningham ML, Borchardt A, Locke JB, Abraham S, Haley G, Kwan BP, Hall C, Hough GW, Shaw KJ, Finn J.

J Med Chem. 2013 Feb 28;56(4):1748-60. doi: 10.1021/jm301756m. Epub 2013 Feb 12.

PMID:
23362938
15.

Genetic environment and stability of cfr in methicillin-resistant Staphylococcus aureus CM05.

Locke JB, Rahawi S, Lamarre J, Mankin AS, Shaw KJ.

Antimicrob Agents Chemother. 2012 Jan;56(1):332-40. doi: 10.1128/AAC.05420-11. Epub 2011 Oct 24.

16.

Differential expression and intrachromosomal evolution of the sghC1q genes in zebrafish (Danio rerio).

Carland TM, Locke JB, Nizet V, Gerwick L.

Dev Comp Immunol. 2012 Jan;36(1):31-8. doi: 10.1016/j.dci.2011.05.013. Epub 2011 Jun 6.

PMID:
21683091
17.

Low fitness cost of the multidrug resistance gene cfr.

LaMarre JM, Locke JB, Shaw KJ, Mankin AS.

Antimicrob Agents Chemother. 2011 Aug;55(8):3714-9. doi: 10.1128/AAC.00153-11. Epub 2011 Jun 6.

18.

Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.

Locke JB, Morales G, Hilgers M, G C K, Rahawi S, José Picazo J, Shaw KJ, Stein JL.

Antimicrob Agents Chemother. 2010 Dec;54(12):5352-5. doi: 10.1128/AAC.00714-10. Epub 2010 Sep 13.

19.

Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, G C K, Picazo JJ, Im W, Shaw KJ, Stein JL.

Antimicrob Agents Chemother. 2010 Dec;54(12):5337-43. doi: 10.1128/AAC.00663-10. Epub 2010 Sep 13.

20.

Evaluation of Streptococcus iniae killed bacterin and live attenuated vaccines in hybrid striped bass through injection and bath immersion.

Locke JB, Vicknair MR, Ostland VE, Nizet V, Buchanan JT.

Dis Aquat Organ. 2010 Mar 9;89(2):117-23. doi: 10.3354/dao02192.

21.

Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.

Locke JB, Hilgers M, Shaw KJ.

Antimicrob Agents Chemother. 2009 Dec;53(12):5275-8. doi: 10.1128/AAC.01032-09. Epub 2009 Oct 5.

22.

The novel polysaccharide deacetylase homologue Pdi contributes to virulence of the aquatic pathogen Streptococcus iniae.

Milani CJ, Aziz RK, Locke JB, Dahesh S, Nizet V, Buchanan JT.

Microbiology. 2010 Feb;156(Pt 2):543-54. doi: 10.1099/mic.0.028365-0. Epub 2009 Sep 17.

23.

Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Locke JB, Hilgers M, Shaw KJ.

Antimicrob Agents Chemother. 2009 Dec;53(12):5265-74. doi: 10.1128/AAC.00871-09. Epub 2009 Sep 14.

24.

The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing.

Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, Sriskandan S, Hanski E, Nizet V.

Cell Host Microbe. 2008 Aug 14;4(2):170-8. doi: 10.1016/j.chom.2008.07.002.

25.

Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine development.

Locke JB, Aziz RK, Vicknair MR, Nizet V, Buchanan JT.

PLoS One. 2008 Jul 30;3(7):e2824. doi: 10.1371/journal.pone.0002824.

26.

Streptococcus iniae beta-hemolysin streptolysin S is a virulence factor in fish infection.

Locke JB, Colvin KM, Varki N, Vicknair MR, Nizet V, Buchanan JT.

Dis Aquat Organ. 2007 Jun 7;76(1):17-26.

27.

Streptococcus iniae capsule impairs phagocytic clearance and contributes to virulence in fish.

Locke JB, Colvin KM, Datta AK, Patel SK, Naidu NN, Neely MN, Nizet V, Buchanan JT.

J Bacteriol. 2007 Feb;189(4):1279-87. Epub 2006 Nov 10.

Supplemental Content

Loading ...
Support Center